Cellular Biotechnology Unit, Instituto de Salud Carlos III, Madrid, Spain.
Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Firenze, Italy.
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001703.
Osteosarcoma is the most common malignant solid tumor that affects bones, however, survival rates of patients with relapsed osteosarcoma have not improved in the last 30 years. Oncolytic virotherapy, which uses viruses designed to selectively replicate in cancer cells, has emerged as a promising treatment for solid tumors. Our group uses mesenchymal stem cells (MSCs) to transport oncolytic adenoviruses (OAds) to the tumor site, a therapeutic strategy called Celyvir. This treatment has been already applied in human patients, canine patients and different mouse models. In parallel, previous results have probed that administration of granulocyte-colony stimulating factor (G-CSF) increased immune infiltration in tumors. We then hypothesized that the mobilization of immune cells by G-CSF may increase the antitumor efficacy of Celyvir treatment by increasing the immune infiltration into the tumors.
In this study, we use a murine version of Celyvir consisting in murine MSCs carrying the murine OAd dlE102-here called OAd-MSCs-in an immunocompetent model of osteosarcoma. We tested the antitumoral efficacy of the combination of OAd-MSCs plus G-CSF.
Our results show that treatment with OAd-MSCs or the union of OAd-MSCs with G-CSF (Combination) significantly reduced tumor growth of osteosarcoma in vivo. Moreover, treated tumors presented higher tumor infiltration of immune cells-especially tumor-infiltrating lymphocytes-and reduced T cell exhaustion, which seems to be enhanced in tumors treated with the Combination. The comparison of our results to those obtained from a cohort of pediatric osteosarcoma patients showed that the virotherapy induces immunological changes similar to those observed in patients with good prognosis.
The results open the possibility of using cellular virotherapy for the treatment of bone cancers. Indeed, its combination with G-CSF may be considered for the improvement of the therapy.
骨肉瘤是最常见的恶性骨肿瘤,但在过去 30 年中,复发性骨肉瘤患者的生存率并未提高。溶瘤病毒治疗是一种利用专门在癌细胞中复制的病毒的有前途的治疗实体瘤的方法。我们的小组使用间充质干细胞(MSCs)将溶瘤腺病毒(OAds)输送到肿瘤部位,这是一种称为 Celyvir 的治疗策略。这种治疗方法已经在人类患者、犬科患者和不同的小鼠模型中应用。同时,之前的结果表明粒细胞集落刺激因子(G-CSF)的给药增加了肿瘤中的免疫浸润。因此,我们假设 G-CSF 对免疫细胞的动员可能通过增加肿瘤中的免疫浸润来提高 Celyvir 治疗的抗肿瘤疗效。
在这项研究中,我们使用了一种鼠源 Celyvir,它由携带鼠源 OAd dlE102 的鼠源 MSCs 组成,称为 OAd-MSCs,用于骨肉瘤的免疫功能正常模型。我们测试了 OAd-MSCs 加 G-CSF 联合治疗的抗肿瘤疗效。
我们的结果表明,OAd-MSCs 或 OAd-MSCs 与 G-CSF(联合)联合治疗显著降低了骨肉瘤在体内的肿瘤生长。此外,治疗后的肿瘤表现出更高的免疫细胞浸润-特别是肿瘤浸润淋巴细胞-和减少 T 细胞衰竭,这似乎在联合治疗的肿瘤中得到增强。将我们的结果与一组儿科骨肉瘤患者的结果进行比较表明,病毒治疗诱导的免疫变化与预后良好的患者观察到的变化相似。
这些结果为使用细胞病毒疗法治疗骨癌开辟了可能性。事实上,将其与 G-CSF 联合使用可能被认为是改善该疗法的一种方法。